Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | VHL loss |
Gene Variant Detail | |
Relevant Treatment Approaches | mTORC1 Inhibitor VEGFR Inhibitor (Pan) VEGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
VHL loss | renal cell carcinoma | sensitive | VEGFR Inhibitor (Pan) | Bevacizumab | Preclinical | Actionable | In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246). | 22931246 |
VHL loss | renal cell carcinoma | sensitive | ELR510444 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124). | 22295124 | |
VHL loss | renal cell carcinoma | sensitive | BPTES | Preclinical - Cell culture | Actionable | In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230). | 28346230 | |
VHL loss | renal cell carcinoma | sensitive | Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230). | 28346230 | |
VHL loss | renal cell carcinoma | sensitive | Olaparib + Telaglenastat | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230). | 28346230 | |
VHL loss | renal cell carcinoma | sensitive | BPTES + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230). | 28346230 |